MOTS-c is a 16-amino-acid peptide with an unusual origin: it's encoded not by nuclear DNA, but by a small stretch of mitochondrial DNA, the genetic material inside the cell's energy-producing organelles. First described by researchers in 2015, it has become one of the more actively studied "mitochondrial-derived peptides" in metabolic research, and, like KPV, it recently cleared a specific regulatory step worth putting in context.

What It Is

Mitochondria carry their own small genome, separate from the DNA in a cell's nucleus, and MOTS-c is translated from a region of that mitochondrial DNA that overlaps the gene for the 12S ribosomal RNA. Once produced, it appears to act as a signaling molecule that communicates between mitochondria and the rest of the cell, including moving into the cell's nucleus under certain conditions, such as metabolic stress or exercise, to influence gene expression related to metabolism.

What the Research Shows

The original 2015 research, published in Cell Metabolism, found that MOTS-c activated AMPK, a key cellular energy-sensing enzyme, and improved insulin sensitivity and reduced markers associated with obesity in mice fed a high-fat diet. More recent laboratory research has extended this work, including 2025 studies examining whether MOTS-c can help prevent pancreatic islet cell senescence in mouse models of diabetes, and whether it can help restore mitochondrial respiration in diabetic heart tissue. This is a substantive, ongoing area of basic science research. It is also, at this point, entirely preclinical: MOTS-c's effects have been studied in mice and in cell culture, not in registered human clinical trials, and no controlled human study currently supports using it for metabolic health, exercise performance, or anti-aging purposes, the claims it's most often marketed around.

Regulatory Status

MOTS-c is not FDA-approved for any use. It was one of four peptides an FDA Pharmacy Compounding Advisory Committee panel voted to recommend for the 503A bulk drug substances list at its July 23-24, 2026 meeting, alongside BPC-157, TB-500, and KPV, discussed in this site's coverage of that vote. As with the others, that's a committee recommendation the FDA still has to act on, not a final approval, and it wouldn't make MOTS-c available without a prescription even if finalized.

Safety Considerations

Because human trial data doesn't exist, there's no established human dosing information, no confirmed human side-effect profile, and no long-term safety data for MOTS-c. Products currently marketed as MOTS-c are sold as unregulated research chemicals, meaning purity and accurate labeling aren't independently verified.

The Bottom Line

MOTS-c sits at a genuinely interesting point in basic metabolic research, with a specific, well-documented mechanism and an expanding animal-model evidence base. That's a meaningfully different starting point than some other research-chemical peptides, but it still falls well short of the human clinical evidence needed to know whether it's safe or effective for any use in people. Its advisory-committee recommendation is a regulatory development, not a research result, and shouldn't be read as evidence that MOTS-c works. Talk to a doctor before using any unapproved compound, particularly given the complete absence of human safety data here.